- Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.
- Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.
Potential merger discussions involving major pharmaceutical companies like Eli Lilly, AstraZeneca, and AbbVie are underway.
2 reports, 1 independent
Updated Aug 3
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Potential merger discussions involving major pharmaceutical companies like Eli Lilly, AstraZeneca, and AbbVie are underway.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
AstraZeneca
British-Swedish pharmaceutical company
-
AbbVie
pharmaceutical company
Related events
- AbbVie and Eli Lilly are competing in the pharmaceutical market.
- Eli Lilly and AstraZeneca are involved in drug development and market competition, with the FDA issuing approvals and legal actions involving both companies.
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- AstraZeneca and Tarsus Pharmaceuticals, Inc. are two healthcare companies that are currently competing for investment.